
Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder
Betsy Goodfellow | April 22, 2024 | News story | Research and Development | Kaerus Bioscience, Neurolentech, Neurology, neurodevelopmental disorders, neurology
Neurolentech has announced that it has entered into a technology access partnership with Kaerus Bioscience, with the aim of driving advancement in neurodevelopmental disorder research.
Neurolentech has a focus on epilepsy and related genetic neurodevelopmental disorders (NDDs) while Kaerus Bioscience is a biotech company focusing on scientific advances into treatment realities for patients who have rare genetic syndromes of neurodevelopment.
The agreement is expected to allow Kaerus Bioscience to ‘access Neurolentech’s NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens to drive advances in neurodevelopmental disorders research’, according to the company’s press release.
This partnership is part of Neurolentech’s goal to advance drug discovery for NDDs as well as reinforcing its NDD Drug Discovery Platform as a valuable for researchers and industry partners.
Fiona Neilsen, chief executive officer of Neurolentech, commented: “We are excited to collaborate with Kaerus Bioscience in advancing their programmes in the field of neurodevelopmental disorders. Our platform’s unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies.”
Betsy Goodfellow
Related Content

Esaote presents new MRI system to support brain glioma surgeries
Gliomas are among the most common primary malignant brain tumours

Kaerus Bioscience secures FDA approval for rare genetic disorder treatment
Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation …

Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …






